がんケアにおけるゲノミクス市場- 世界の産業規模、シェア、動向、機会、予測、製品別、技術別、用途別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

がんケアにおけるゲノミクスの世界市場規模は2024年に157億3,000万米ドルで、予測期間には402億2,000万米ドルに達すると予測され、2030年までのCAGRは16.91%です。

世界のがんケアにおけるゲノミクス市場は、精密医療の普及とゲノム技術の進歩により大きな成長を遂げています。がんの診断と治療における次世代シーケンサー（NGS）、リキッドバイオプシー、人工知能の統合は、がんケアを一変させました。がん罹患率の上昇と個別化治療のニーズの高まりが、ゲノムベースのソリューションに対する需要を加速させています。製薬会社、研究機関、診断会社はバイオマーカー主導のがん治療を開発するために協力しており、治療効果と患者の転帰を向上させています。ゲノムデータ解析ツールやバイオインフォマティクス・プラットフォームの絶え間ない進化が市場の拡大をさらに後押しし、ゲノム解析は現代のがん治療に不可欠な要素となっています。

市場促進要因

ゲノムシークエンシングの進歩

主な市場課題

コストとアクセシビリティ

主要市場動向

リキッドバイオプシーと早期発見

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のがんケアにおけるゲノミクス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（機器、消耗品、サービス）
  • 技術別（ゲノムシークエンシング、PCR、マイクロアレイ、核酸抽出・精製、その他）
  • 用途別（診断、個別化医療、医薬品の発見と開発、調査）
  • エンドユーザー別（病院、研究機関・学術機関、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のがんケアにおけるゲノミクス市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のがんケアにおけるゲノミクス市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のがんケアにおけるゲノミクス市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のがんケアにおけるゲノミクス市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのがんケアにおけるゲノミクス市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（該当する場合）
• 製品の発売（該当する場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Illumina Inc
• Agilent Technologies, Inc.
• Roche Diagnostics
• Cancer Genetics, Inc.
• Bio-Rad Laboratories Inc
• Sigma-Aldrich Corp
• QIAGEN NV
• GE Healthcare Inc
• Life Technologies Corp
• Quest Diagnostics Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Genomics in Cancer Care Market was valued at USD 15.73 Billion in 2024 and is expected to reach USD 40.22 Billion in the forecast period with a CAGR of 16.91% through 2030. The Global Genomics in Cancer Care Market is experiencing significant growth due to the increasing adoption of precision medicine and advancements in genomic technologies. The integration of next-generation sequencing (NGS), liquid biopsy, and artificial intelligence in cancer diagnostics and treatment has transformed oncology care. Rising cancer prevalence and the growing need for personalized therapies have accelerated the demand for genomic-based solutions. Pharmaceutical companies, research institutions, and diagnostic firms are collaborating to develop biomarker-driven cancer therapies, enhancing treatment efficacy and patient outcomes. The continuous evolution of genomic data analysis tools and bioinformatics platforms further supports the market's expansion, making genomics an essential component of modern cancer care.

Key Market Drivers

Advancements in Genomic Sequencing

In the ever-evolving landscape of cancer care, genomic sequencing has emerged as a potent tool, significantly shaping the Global Genomics in Cancer Care Market. Advancements in genomic sequencing, particularly Next-Generation Sequencing (NGS), have enabled comprehensive molecular profiling of cancer. This allows researchers and healthcare providers to analyze a patient's entire genome to identify mutations, alterations, and genetic markers associated with cancer, facilitating more accurate diagnoses and tailored treatment strategies.

The Cancer Genome Atlas (TCGA), a landmark program by the National Cancer Institute (NCI), has molecularly characterized over 20,000 primary cancer and matched normal samples across 33 cancer types. This extensive dataset, comprising more than two petabytes of genomic data, is publicly available and aids the cancer research community in improving prevention, diagnosis, and treatment strategies.

Genomic sequencing allows for the identification of specific genetic mutations driving a patient's cancer, which is invaluable in developing targeted therapies. Pharmaceutical companies leverage genomic insights to create drugs that precisely target the genetic abnormalities responsible for cancer growth, increasing treatment effectiveness and reducing side effects.

Personalized medicine, based on genomic sequencing, has revolutionized cancer care. By analyzing a patient's genetic makeup, oncologists can tailor treatment plans to the individual, optimizing therapy selection and dosage. This approach not only improves patient outcomes but also enhances the overall quality of life during treatment.

Genomic sequencing also plays a crucial role in early detection and prevention. Genetic testing can identify individuals with a higher risk of developing certain cancers, enabling early interventions and proactive health management. Additionally, screening for genetic markers associated with cancer allows for earlier diagnosis and intervention, increasing the chances of successful treatment.

The wealth of data generated through genomic sequencing is a goldmine for researchers and healthcare providers. Advanced data analytics and bioinformatics tools are employed to interpret and extract meaningful insights from genomic data, leading to more informed clinical decisions and supporting ongoing research into new cancer therapies and diagnostic tools.

Advancements in genomic sequencing have driven down the cost of sequencing, making it more accessible for patients and healthcare providers. As sequencing becomes more affordable, its adoption in clinical settings becomes more widespread, further fueling market growth.

In summary, the integration of genomic sequencing into cancer care has transformed the approach to diagnosis, treatment, and prevention, driving significant advancements in the Global Genomics in Cancer Care Market.

Key Market Challenges

Cost and Accessibility

The high cost of genomic technologies and limited accessibility to advanced cancer care remain significant challenges in the Global Genomics in Cancer Care Market. Next-generation sequencing (NGS), whole genome sequencing, and other genomic profiling techniques require expensive instruments, reagents, and bioinformatics infrastructure, making them unaffordable for many healthcare providers and patients. The cost burden is further exacerbated by the need for specialized expertise to interpret complex genomic data, increasing operational expenses for diagnostic laboratories and hospitals. Many low- and middle-income countries struggle to integrate genomic-based cancer diagnostics into their healthcare systems due to budget constraints and the lack of reimbursement policies for these advanced tests.

Limited accessibility to genomic cancer care is another critical issue, particularly in remote and underserved regions. Many healthcare facilities lack the necessary infrastructure to conduct in-house genomic testing, leading to delays in diagnosis and treatment initiation. Patients in such areas often need to travel long distances to access specialized centers, increasing financial and logistical burdens. The disparity in access to genomic testing is also evident within high-income countries, where only major medical centers offer comprehensive genomic profiling, while smaller hospitals and clinics face resource limitations. The absence of standardized regulations and inconsistent reimbursement policies across different regions further hinder the widespread adoption of genomic technologies in oncology.

Key Market Trends

Liquid Biopsies and Early Detection

The Global Genomics in Cancer Care Market is experiencing a significant shift toward liquid biopsies and early detection, driven by advancements in next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis. Liquid biopsy is emerging as a revolutionary tool for non-invasive cancer diagnostics, enabling real-time monitoring of tumor progression and treatment response. Traditional tissue biopsies are often invasive, time-consuming, and limited in capturing tumor heterogeneity. Liquid biopsies, on the other hand, provide a comprehensive genomic profile by detecting genetic alterations in circulating biomarkers such as ctDNA, circulating tumor cells (CTCs), and extracellular vesicles in blood samples. The increasing adoption of this technology is improving early cancer detection rates, enhancing treatment personalization, and reducing the need for repeated invasive procedures.

Key Market Players

• Illumina Inc
• Agilent Technologies, Inc.
• Roche Diagnostics
• Cancer Genetics, Inc.
• Bio-Rad Laboratories Inc
• Sigma-Aldrich Corp
• QIAGEN NV
• GE Healthcare Inc
• Life Technologies Corp
• Quest Diagnostics Inc

Report Scope:

In this report, the Global Genomics in Cancer Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomics in Cancer Care Market, By Product:

• Instruments
• Consumables
• Services

Genomics in Cancer Care Market, By Technology:

• Genome Sequencing
• PCR
• Microarray
• Nucleic Acid Extraction and Purification
• Others

Genomics in Cancer Care Market, By Application:

• Diagnostics
• Personalized Medicine
• Drug Discovery & Development
• Research

Genomics in Cancer Care Market, By End User:

• Hospitals
• Research Institutes & Academic Institutes
• Others

Genomics in Cancer Care Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genomics in Cancer Care Market.

Available Customizations:

Global Genomics in Cancer Care market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Genomics in Cancer Care Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Consumables, Services)
  • 5.2.2. By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification, Others)
  • 5.2.3. By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research)
  • 5.2.4. By End User (Hospitals, Research Institutes & Academic Institutes, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Genomics in Cancer Care Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genomics in Cancer Care Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Genomics in Cancer Care Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Genomics in Cancer Care Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Genomics in Cancer Care Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Genomics in Cancer Care Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Genomics in Cancer Care Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Genomics in Cancer Care Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Genomics in Cancer Care Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Genomics in Cancer Care Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Genomics in Cancer Care Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Genomics in Cancer Care Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Genomics in Cancer Care Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Genomics in Cancer Care Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Genomics in Cancer Care Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Genomics in Cancer Care Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Genomics in Cancer Care Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Genomics in Cancer Care Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Genomics in Cancer Care Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Genomics in Cancer Care Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Genomics in Cancer Care Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Genomics in Cancer Care Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Genomics in Cancer Care Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Genomics in Cancer Care Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Illumina Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Agilent Technologies, Inc.
• 14.3. Roche Diagnostics
• 14.4. Cancer Genetics, Inc.
• 14.5. Bio-Rad Laboratories Inc
• 14.6. Sigma-Aldrich Corp
• 14.7. QIAGEN NV
• 14.8. GE Healthcare Inc
• 14.9. Life Technologies Corp
• 14.10. Quest Diagnostics Inc

15. Strategic Recommendations

16. About Us & Disclaimer